Eliem Therapeutics, Inc. (ELYM)

8.81 +0.12 (+1.38%) At close: 04:00PM EDT

Eliem Therapeutics, Inc.

PMB #117, 2801 Centerville Road
1st Floor
Wilmington, DE 19808-1609
United States
877 354 3689
https://eliemtx.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 9

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Andrew Levin M.D., Ph.D.	Principal Financial Officer, Co-Founder & Executive Chairman	65.39k	N/A	1977
Dr. Valerie Morisset Ph.D.	Chief Scientific Officer and Executive VP of Research & Development	1.08M	N/A	1970
Ms. Emily Pimblett	Chief Accounting Officer	N/A	N/A	1984
Ms. Jo Palmer-Phillips Ph.D.	Chief Development Officer	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Eliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.

Corporate governance

Eliem Therapeutics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.